ADAPTIMMUNE THERAPEUTICS Reports Q4 FY2022 Earnings Results on December 31, 2022
Earnings Overview ADAPTIMMUNE THERAPEUTICS ($NASDAQ:ADAP) announced their Q4 FY2022 earnings results on December 31 2022, with total revenue increasing 24.7% [...]
Barclays PLC Boosts Stake in Adaptimmune Therapeutics plc.
Trending News ☀️ ADAPTIMMUNE ($NASDAQ:ADAP): Sumitomo Realty & Development has announced its launch into the UK real estate market with [...]
Adaptimmune Therapeutics CEO Adrian Rawcliffe Sells 10,057 Shares
Trending News ☀️ Adaptimmune Therapeutics ($NASDAQ:ADAP) plc is a clinical-stage biopharmaceutical company focused on developing novel, engineered T-cell therapies for [...]
Adaptimmune Therapeutics stock is up today on strong showings from the company’s anti-cancer cell therapies.
Trending News ☀️ Adaptimmune Therapeutics ($NASDAQ:ADAP) is a company that focuses on developing cell therapies to treat cancer. First, the [...]
Adaptimmune Therapeutics plc : How investors can get the most out of their investments
Trending News 🌥️ Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development of T-cell therapies for the [...]
